Jaguar Health details GI drug pipeline and deals | JAGX Annual Report (10-K)
Jaguar Health’s 10-K outlines a crofelemer-centered GI portfolio, a $16M non-dilutive Mytesi license with Future Pak, advancing orphan programs in MVID and SBS-IF, and NP-300’s...